ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A Prospective and Randomized Study of Conversion from Tacrolimus to Cyclosporine A to Improve Glucose Metabolism in Patients With New-Onset Diabetes Mellitus After Renal Transplantation

K. Wissing,1 D. Abramowicz,2 L. Weekers,3 K. Budde,4 T. Rath,5 O. Witzke,6 D. Kuypers.7

1Universitair Ziekenhuis Brussel, Brussels, Belgium
2Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium
3Centre Hospitalier Universitaire Liège, Liège, Belgium
4Charité
Universitätsmedizin Berlin, Berlin, Germany
5Westpfalz Klinikum Kaiserslautern, Kaiserslautern, Germany
6Universitätsklinikum Essen, Essen, Germany
7Universitair Ziekenhuis Leuven, Leuven, Belgium.

Meeting: 2015 American Transplant Congress

Abstract number: 382

Keywords: FK506, Kidney transplantation, Metabolic complications

Session Information

Session Name: Concurrent Session: Kidney: Cardiovascular and Metabolic

Session Type: Concurrent Session

Date: Tuesday, May 5, 2015

Session Time: 2:15pm-3:45pm

 Presentation Time: 3:15pm-3:27pm

Location: Terrace I-III

Background: The present prospective and randomized study was designed to assess whether conversion from tacrolimus (Tac) to cyclosporine A (CsA) can reverse posttransplantation diabetes mellitus in at least 25% of patients.

Methods: Patients with NODAT according to the 2005 ADA criteria, persisting at least 6 month after renal transplantation, were randomized to either replacement of Tac with CsA or continuation of their Tac-based regimen. Randomization was stratified for type of glucose-lowering therapy (insulin, oral agents, none), steroid therapy and HCV status.

Results: 84 out of 87 randomized patients received the allocated intervention (CsA N=43; Tac N=41). Half of the patients in both arms were steroid-free at the moment of inclusion. At one year, 14 of 41 patients with complete data in the CsA arm (34%; 95%CI 19% to 49%) were free of diabetes vs. 4 of 39 patients (10%; 95%CI 3% to 20%) in the Tac arm (P=0.01). Among 61 patients receiving glucose-lowering therapy at inclusion reversibility of NODAT was observed in 5 of 31 patients (16%) in the CsA arm versus none of the 30 patients in the Tac arm (P=0.05). At 12 months 16/41 patients (39%) in the CsA arm were off glucose-lowering medication vs. 5/38 patients (13%) of in the tacrolimus arm (P=0.01). The CsA group reached a significantly lower HbA1c as compared to the TAC group (6.0±0.9% vs. 7.1±1.7%; P=0.002). During the follow-up one borderline and one acute cellular rejection occurred in each arm (P=NS). Serum creatinine increased from 1.41 mg/dl to 1.61 mg/dl in the CsA arm (P<0.0001) and from 1.47 mg/dl to 1.59 mg/dl in the Tac arm (P=0.05) during the one year follow up, without significant between-group differences.

Conclusions: The prospective and randomized REVERSE study shows that conversion from tacrolimus to cyclosporine improves glucose metabolism and reverses new onset diabetes after transplantation in a significant proportion of patients. Conversion did not increase the risk of acute rejection.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Wissing K, Abramowicz D, Weekers L, Budde K, Rath T, Witzke O, Kuypers D. A Prospective and Randomized Study of Conversion from Tacrolimus to Cyclosporine A to Improve Glucose Metabolism in Patients With New-Onset Diabetes Mellitus After Renal Transplantation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/a-prospective-and-randomized-study-of-conversion-from-tacrolimus-to-cyclosporine-a-to-improve-glucose-metabolism-in-patients-with-new-onset-diabetes-mellitus-after-renal-transplantation/. Accessed May 27, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences